Insight brief
See The Whole Board
The Inflation Reduction Act of 2022, and the complex chess game now in play for pharmaceutical manufacturers
Sep 09, 2022

The Inflation Reduction Act of 2022 is poised to be a watershed event for the U.S. healthcare system. The ripple effects of provisions designed to transform price negotiations, funding sources, and patient burden will be both swift, and extensive. Inaction or avoidance will not be rewarded.

Organizations across the ecosystem will need to quickly separate theory from reality, and strategically prepare for significant change.

In this brief, a team of IQVIA industry experts – from policy and market access to brand strategy and financial planning – establish the contours of the conversation and elucidate both short-term impact and long-term implications.

U.S. Progress Point Subscribers' Circle: First-looks, exclusive content, and more.
Contact Us